JAMA Network Home
Sign In
Original Investigation

Safety and Effects of Gildeuretinol Acetate on Retinal Atrophic Lesions in Stargardt Disease

JAMA Ophthalmology 10.1001/jamaophthalmol.2026.3662

September 03, 2026 at 11:00 AM EDT

Read the full article

In the TEASE-1 randomized clinical trial, the primary efficacy end point of retinal atrophic lesion growth from 6 to 24 months was 0.05 mm/y greater on average in the untreated group (placebo and NH) than the gildeuretinol acetate group. Further research is needed to determine the clinical relevance of this end point.

Corresponding Author: Leonide Saad, PhD, Alkeus Pharmaceuticals, 44 Brattle St, 2nd Floor, Cambridge, MA 02138 (leonide@gmail.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jamaophthalmology/fullarticle/10.1001/jamaophthalmol.2026.3662?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=090326

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks